An Open Label, Single Center Study to Evaluate the Safety and Imaging Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Mild to Moderate Alzheimer's Disease (AD) and Patients With Progressive Supranuclear Palsy (PSP) After i.v. Application of [18F]PI-2620 With High and Low Specific Activity
Latest Information Update: 15 May 2024
At a glance
- Drugs PI 2620 (Primary)
- Indications Alzheimer's disease; Progressive supranuclear palsy
- Focus Diagnostic use
- Sponsors Life Molecular Imaging
- 10 May 2024 Status changed from active, no longer recruiting to completed.
- 25 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Sep 2023.
- 14 Dec 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.